After-Hours Movers: Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Citi Reiterates $7 PT on Cano Health (CANO), Says Takeout Could Be Worth $14 on Roughly 2x Revenue
September 23, 2022 12:18 PM EDTCiti analyst Jason Cassorla reiterated a Buy rating and $7.00 price target on Cano Health (NYSE: CANO).
The analyst comments "Another Takeout Headline Not Surprising: Multiple headlines over the past ~six months have suggested CANO could potentially be acquired. To this end, CANO traded at ~1.0x our 2023E revenue at an unaffected price of $6.31 (September 21st close), which compares to its SPAC merger multiple at ~3x forward revenue, and other recent deals in the space including AMZNs... More
